# A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

> **NCT03069326** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT03069326
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-02-27
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069326, "A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03069326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*